## Diagnosis: Megaloblastic Anemia due to Vitamin B12 Deficiency (with Co-existing Folate Deficiency Possible) ### Clinical Presentation Analysis **Key Point:** The combination of pancytopenia, hypersegmented neutrophils, macro-ovalocytes, hypercellular megaloblastic bone marrow, and serum B12 of 180 pg/mL (below the 200 pg/mL lower limit of normal) is diagnostic of vitamin B12 deficiency as the primary etiology. In the Indian subcontinent, this is most commonly due to dietary insufficiency (strict vegetarian diet), pernicious anemia, or malabsorption (tropical sprue). **High-Yield:** In India, vitamin B12 deficiency causes include: - Dietary insufficiency (vegetarian/vegan diet — most common in India) - Pernicious anemia (autoimmune destruction of parietal cells → loss of intrinsic factor) - Malabsorption syndromes (tropical sprue, celiac disease, post-gastrectomy) - Diphyllobothrium latum (fish tapeworm) — competes for B12 ### Why Folic Acid Must Be Co-administered with B12 **Clinical Pearl:** Standard practice in megaloblastic anemia is to administer **both B12 and folic acid** simultaneously, because: 1. **Folate trap mechanism:** B12 deficiency traps folate as methyltetrahydrofolate (methyl-THF), rendering it unavailable for DNA synthesis. Correcting B12 alone may be insufficient if concurrent folate deficiency exists. 2. **Concurrent deficiency is common:** In nutritionally deficient populations (rural India), combined B12 and folate deficiency frequently coexist. Treating B12 alone without addressing folate risks incomplete hematologic recovery. 3. **Masking risk (reverse):** Giving folate alone in B12 deficiency corrects hematologic parameters but allows subacute combined degeneration of the spinal cord to progress — a neurological catastrophe. Hence, both must be given together. | Scenario | Risk | |---|---| | B12 alone (Option A) | May miss concurrent folate deficiency; incomplete recovery | | Folate alone | Masks B12 deficiency; neurological damage progresses | | B12 + Folate (Option C) | Addresses both deficiencies; safe and complete | ### Correct Management Sequence 1. **Confirm diagnosis:** B12 level + peripheral smear + bone marrow (already done in this case) 2. **Check serum/RBC folate** before or at the time of starting treatment 3. **Start both B12 and folic acid simultaneously:** - Cyanocobalamin: 1000 μg IM weekly × 6 weeks, then monthly maintenance - Folic acid: 5 mg oral daily × 3–6 months 4. **Monitor response:** Reticulocyte count rises by day 3–5; Hb improves by week 2–4 5. **Investigate underlying cause:** Intrinsic factor antibodies, parietal cell antibodies, dietary history **Mnemonic — B12 Deficiency Management: "FOLD"** - **F**olate level (always check and co-treat) - **O**ther causes (dietary, malabsorption, pernicious anemia) - **L**evel of B12 (confirmed low at 180 pg/mL) - **D**ual therapy (B12 + folate together) ### Why Other Options Are Incorrect - **Option A (B12 alone):** Incomplete management. Does not address possible concurrent folate deficiency, which is common in nutritionally deficient rural populations. Risks incomplete hematologic recovery. The correct answer is dual therapy (Option C). - **Option B (Bone marrow biopsy + immunophenotyping):** The bone marrow already shows megaloblastic changes — a benign, nutritional etiology. There are no features (blasts, Auer rods, lymphadenopathy pattern) to suggest acute leukemia. Immunophenotyping is unnecessary and delays treatment. - **Option D (Corticosteroids + splenectomy):** These are reserved for immune-mediated cytopenias (ITP, AIHA, Evans syndrome), not nutritional megaloblastic anemia. **[cite: Harrison's Principles of Internal Medicine, 21st ed., Ch. 96 — Megaloblastic Anemias; KD Tripathi Essentials of Medical Pharmacology, 8th ed.]**
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.